Results 31 to 40 of about 271,759 (355)

How to spot ocular abnormalities in progressive supranuclear palsy? A practical review

Translational Neurodegeneration, 2019
Background For parkinsonian disorders, progressive supranuclear palsy (PSP) continues to be significant for differential diagnosis. PSP presents a range of ocular abnormalities that have been suggested as optional tools for its early detection, apart ...
Onanong Phokaewvarangkul, Roongroj Bhidayasiri   +1 more
doaj   +1 more source

Noradrenaline and Parkinson's Disease [PDF]

Frontiers in Systems Neuroscience, 2011
Parkinson's disease (PD) is characterized by the degeneration of dopamine (DA) neurons in the substantia nigra pars compacta, and motor symptoms including bradykinesia, rigidity, and tremor at rest. These symptoms are exhibited when striatal dopamine concentration has decreased by around 70%.
Claire eDelaville, Philippe eDe Deurwaerdère, Abdelhamid eBenazzouz, Abdelhamid eBenazzouz   +3 more
openaire   +5 more sources

LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate [PDF]

, 2016
Background Lrrk2, a gene linked to Parkinson\u2019s disease, encodes a large scaffolding protein with kinase and GTPase activities implicated in vesicle and cytoskeletal-related processes.
Arrigoni, Giorgio, Belluzzi, Elisa, Beltramini, Mariano, Bubacco, Luigi, Carrion, Maria Per\ue8z, Cirnaru, Maria Daniela, Civiero, Laura, Cogo, Susanna, Franchin, Cinzia, Gonnelli, Adriano, Greggio, Elisa, Marte, Antonella, Onofri, Franco, Piccoli, Giovanni, Plotegher, Nicoletta, Russo, Isabella   +15 more
core   +5 more sources

Two-year trajectory of fall risk in people with Parkinson disease: a latent class analysis [PDF]

, 2016
Published in final edited form as: Arch Phys Med Rehabil. 2016 March ; 97(3): 372–379.e1. doi:10.1016/j.apmr.2015.10.105.OBJECTIVE: To examine fall risk trajectories occurring naturally in a sample of individuals with early to middle stage Parkinson ...
Cavanaugh, James T., Dibble, Leland E., Duncan, Ryan P., Earhart, Gammon M., Ellis, Theresa D., Ford, Matthew P., Foreman, K. Bo, Paul, Serene S., Thackeray, Anne   +8 more
core   +1 more source

Parkinson's disease

Medicine, 2016
Parkinson's disease (PD) is a common neurodegenerative condition, affecting 2–3% of individuals >65 years of age. Although it is defined as a movement disorder, patients also experience a range of non-motor symptoms, reflecting pathology that is more widespread than originally thought in the peripheral and autonomic nervous system as well as the ...
Williams-Gray, CH, Worth, PF
openaire   +2 more sources

Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background In addition to primary neurodegenerative processes, vascular disorders, such as stroke, can lead to parkinsonism. However, some cardiovascular risk factors, such as smoking and elevated cholesterol levels, are associated with reduced risk of ...
Jens Sundbøll, Szimonetta Komjáthiné Szépligeti, Péter Szentkúti, Kasper Adelborg, Erzsébet Horváth‐Puhó, Lars Pedersen, Victor W. Henderson, Henrik Toft Sørensen   +7 more
doaj   +1 more source

Imaging in Parkinson's Disease [PDF]

Clinical Medicine, 2016
Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by the loss of nigrostriatal dopaminergic neurons and aggregation of misfolded α-synuclein in Lewy bodies. The underlying mechanisms of neurodegeneration in PD are still unknown, and there are no disease-modifying treatments to slow the neurodegenerative processes.
Politis, Marios, Pagano, Gennaro, Niccolini, Flavia   +2 more
openaire   +7 more sources

Balance differences in people with Parkinson disease with and without freezing of gait [PDF]

, 2015
Published in final edited form as: Gait Posture. 2015 September ; 42(3): 306–309. doi:10.1016/j.gaitpost.2015.06.007.BACKGROUND: Freezing of gait (FOG) is a relatively common and remarkably disabling impairment associated with Parkinson disease (PD).
Cavanaugh, James T., Dibble, Leland E., Duncan, Ryan P., Earhart, Gammon M., Ellis, Terry D., Ford, Matthew P., Foreman, K. Bo, Leddy, Abigail L.   +7 more
core   +1 more source

Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease

Frontiers in Cell and Developmental Biology, 2020
Parkinson disease, the second most common movement disorder, is a complex neurodegenerative disorder hallmarked by the accumulation of alpha-synuclein, a neural-specific small protein associated with neuronal synapses. Mutations in the glucocerebrosidase
Tae-Un Han, Richard Sam, Ellen Sidransky
doaj   +1 more source

Cyclodextrins in Parkinson’s Disease [PDF]

Biomolecules, 2018
Parkinson’s disease is a movement disorder characterized by a progressive degeneration of dopaminergic neurons that has been object of study by the scientific community through the last decades. However, nowadays there is still no treatment to cure it, although there are drugs available, with limited efficacy, to relieve the symptoms or replenish the ...
Ana C.F. Ribeiro, Miguel A. Esteso, Marisa C.F. Barros, Marisa C.F. Barros   +3 more
openaire   +4 more sources